What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Surgery
Susan M. Chang focuses on Glioma, Internal medicine, Surgery, Oncology and Pathology.
Her study in Glioma is interdisciplinary in nature, drawing from both Brain tumor, Central nervous system disease and Extent of resection.
Her Central nervous system disease research incorporates elements of Biopsy and Nuclear medicine.
Her Surgery research includes elements of Clinical trial and Hazard ratio.
Her Oncology study combines topics in areas such as Epidermal growth factor receptor, Survival rate, Radiation therapy, Temozolomide and Rash.
Her studies in Pathology integrate themes in fields like Tumor progression and Blood volume.
Her most cited work include:
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2465 citations)
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors (1025 citations)
- Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas (926 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Glioma, Internal medicine, Oncology, Radiation therapy and Surgery.
The concepts of her Glioma study are interwoven with issues in Brain tumor, Pathology and Magnetic resonance imaging.
Her research in Magnetic resonance imaging intersects with topics in Tumor progression, Nuclear medicine and Medical imaging.
Her studies in Temozolomide, Clinical trial, Phases of clinical research, Chemotherapy and Progression-free survival are all subfields of Internal medicine research.
Her studies deal with areas such as Medical physics, Neurologic Oncology and Intensive care medicine as well as Clinical trial.
Her Oncology study deals with Glioblastoma intersecting with Newly diagnosed.
She most often published in these fields:
- Glioma (35.65%)
- Internal medicine (32.52%)
- Oncology (28.70%)
What were the highlights of her more recent work (between 2018-2021)?
- Glioma (35.65%)
- Internal medicine (32.52%)
- Cancer research (10.26%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Glioma, Internal medicine, Cancer research, Clinical trial and Brain tumor.
Her study in the field of Temozolomide is also linked to topics like Patient-reported outcome.
Her Internal medicine research includes themes of Anticonvulsant and Oncology.
Her research integrates issues of Glioblastoma and Chemotherapy in her study of Oncology.
In Clinical trial, Susan M. Chang works on issues like Intensive care medicine, which are connected to Response assessment and Disease.
While the research belongs to areas of Brain tumor, Susan M. Chang spends her time largely on the problem of Cancer, intersecting her research to questions surrounding Neurologic Oncology.
Between 2018 and 2021, her most popular works were:
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (100 citations)
- The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. (87 citations)
- Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. (86 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her main research concerns Glioma, Brain tumor, Intensive care medicine, Clinical trial and Cancer research.
Her Temozolomide study in the realm of Glioma interacts with subjects such as World health.
Her Brain tumor research incorporates themes from Cancer, Internal medicine, Oncology and Magnetic resonance imaging, Radiology.
In the field of Internal medicine, her study on Interquartile range and Tumor progression overlaps with subjects such as Window of opportunity.
The various areas that Susan M. Chang examines in her Oncology study include Retrospective cohort study, Molecular pathogenesis and Glioblastoma.
Susan M. Chang has included themes like Drug action and Pharmacodynamics in her Clinical trial study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
